EUCTR2009-015719-42-FR进行中（未招募）1 期
A 12-week, randomised, double-blind, placebo controlled trial to evaluate the efficacy, quality of life, safety and tolerability of prucalopride in male subjects with chronic constipation
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Movetis NV
- 入组人数
- 374
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Subject is a male out-patient =18 years of age (no upper age limit).
- •2. Subject has a history of constipation, i.e. reports an average of =2 spontaneous
- •bowel movements (SBM)/week and one or more of the following for at least 6
- •months before the selection visit:
- •a) Very hard (little balls) and/or hard stools for at least a quarter of the stools;
- •b) Sensation of incomplete evacuation following for at least a quarter of
- •c) Straining at defecation for at least a quarter of the time.
- •The above criteria are only applicable for SBMs, i.e. BMs not preceded within
- •a period of 24 hours by the intake of a laxative agent or by the use of an enema.
- •Subjects who never have SBMs are considered to be constipated and are
- •eligible for the trial.
- •3. Subject agrees to stop his/her current laxative treatment and is willing to use
- •rescue medication according to the rescue rule [Dulcolax??(bisacodyl)/
- •Main inclusion criteria to be assessed at baseline (randomisation):
- •1. During the run-in period, the subject reports an average of =2 SBM/week that
- •result in a feeling of complete evacuation (SCBM).*
- •This includes subjects who never have SBMs.
- •2. Subject stopped his/her laxative treatment and did not use rescue mediation on
- •more than 75% of days during the run-in period.*
- •3. Subject did not use disallowed medication during the run-in period.
- •* Excluding the first 7 days for subjects using medication influencing bowel habit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects in whom constipation is thought to be drug-induced.
- •2. Subjects using any disallowed medication.
- •3. Subjects suffering from secondary causes of chronic constipation.
研究者
相似试验
进行中（未招募）
1 期
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1 Level: LLT Classification code 10063582 Term: Constipation chronic System Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-GBShire-Movetis NV374
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1Level: LLTClassification code 10063582Term: Constipation chronicSystem Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-BGShire-Movetis NV348
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioChronic constipationEUCTR2009-015719-42-CZShire-Movetis NV348
进行中（未招募）
不适用
A study to evaluate the efficacy, quality of life, side effects and tolerability of long term treatment (12 weeks) with prucalopride in male patients aged =18 years with chronic constipatioMedDRA version: 14.1Level: LLTClassification code 10063582Term: Constipation chronicSystem Organ Class: 100000004856Chronic constipationEUCTR2009-015719-42-DKShire-Movetis NV348
已完成
不适用
Sustained effects of resveratrol on circulatory function in obese adultsEndothelial vasodilator functionCognitive functionCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemMental Health - Studies of normal psychology, cognitive function and behaviourACTRN12611000060943Professor Peter Howe30